Navigation Links
FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease
Date:9/21/2009

LYNBROOK, N.Y., Sept. 16 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration's (FDA) unanimously recommended by a vote of 12 to 0 that XIAFLEX(TM) (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's disease, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers.

"We believe that the Advisory Committee's very supportive vote today for XIAFLEX represents a major advance for both the patients suffering from Dupuytren's disease, as well as for BioSpecifics and its shareholders," stated Thomas L. Wegman, President of BioSpecifics. "We congratulate our partner Auxilium on its thorough and thoughtful presentation today and look forward to the FDA's decision regarding the approval of XIAFLEX."

The Advisory Committee's recommendations are not binding, but will be considered by the FDA in its review of the XIAFLEX BLA. Auxilium Pharmaceuticals, Inc. has licensed the rights to XIAFLEX from BioSpecifics for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Auxilium filed its BLA for XIAFLEX for the treatment of Dupuytren's disease on February 27, 2009 and received a target date under the Prescription Drug User Fee Act (PDUFA) date of August 28, 2009, which has not been updated.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM) product in Europe.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the ability of its partner Auxilium to obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's disease and Peyronie's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments it may receive; the amount of earn out payments it may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under the companies' license agreement for additional indications; the potential benefits of its existing license and development agreements; its estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company's Form 10-K for the year ended December 31, 2008 and the Form 10-Q for the quarter ended June 30, 2009 and any subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Robert Fanning Named to PerfectServe Advisory Board
2. Dr. Stuart Baker Named to PerfectServe Advisory Board
3. William Dwyer Named to PerfectServe Advisory Board
4. Dr. Michael Guthrie Named to PerfectServe Advisory Board
5. Alan Weinstein Named Chairman of PerfectServe Advisory Board
6. Pennsylvania Patient Safety Authority Releases September Advisory
7. Judy Benjamin Named to PerfectServe Advisory Board
8. GENova appoints Dr. Wang Chong to Scientific Advisory Board
9. GENova appoints Dr. Philip Gould to Scientific Advisory Board
10. Dey Issues Advisory
11. Social Security Advisory Board Warns of Consequences of Unsustainable Growth in The Cost of Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... (PRWEB) , ... April 23, 2017 , ... ... and managed services announced the achievement of Cisco Select certification and SMB specialization. ... the United States. , In earning the Select Certification, Altura fulfilled ...
(Date:4/22/2017)... ... 22, 2017 , ... PharmacyChecker.com released its first International Prescription ... 70% when buying medication online from Canadian pharmacies verified in the PharmacyChecker Verification ... countries. The report (chart below) compares U.S. and foreign prices for 20 of ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 ... pair of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners ... stone may have been used to remove decayed dental matter, and that teeth were ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between ... relative proportion of young people involved in violence in the United States. The ...
(Date:4/21/2017)... Wis. (PRWEB) , ... April 21, 2017 , ... ... today announced that its B-595 and B-7569 vinyl label materials ... identification and warning labels are tested to remain intact and legible, for use on ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 The ... Application, Forecast to 2022 report has covered and analysed the ... and information on market size, shares and growth factors. The ... drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
Breaking Medicine Technology: